WHOLESALERS
In 2023, 7 wholesalers sold veterinary medicines to veterinarians, to general and veterinary pharmacies and to other institutions. Four major wholesalers covered 98% of the total veterinary medicinal products market: Zoovetvaru OÜ (51%), Magnum Veterinaaria AS (32%), Optimer OÜ (8%) and Dimedium AS (8%). The total veterinary market share of the other wholesalers remained under 2%.
VETERINARY MEDICINAL PRODUCTS MARKET
The veterinary medicinal products market is expressed in wholesale prices, which includes the price of the manufacturer and wholesaler’s mark-up and does not include the VAT.
In 2023, the veterinary medicinal products market increased 6.9%, reaching to 18.6 million euros.
Figure 1. Estonian veterinary products market in 2019–2023.
Sales to the veterinarians or to the agricultural companies represented by veterinary doctor covered 92% (17.1 million euros) of the total veterinary medicinal products market, in 2023. The sales to the general and veterinary pharmacies were 8% (1.5 million euros) and the sales to the other institutions remained under 1%.
VETERINARY MEDICINAL PRODUCTS MARKET SHARE BETWEEN ATCvet GROUPS
In 2023, based on ATCvet classification three largest ATCvet groups covered 63% of total veterinary medicinal products market: antiparasitic products (QP) 25% (4.7 million euros), immunologicals (QI) 19% (3.6 million euros) and antiinfectives (QJ) 19% (3.6 million euros), followed by musculo-sceletal system (QM) and alimentary tract and metabolism (QA).
Figure 2. Estonian veterinary medicinal products market share between ATCvet groups in 2019–2023
Antiparasitic Products
The turnover of antiparasitic products had the highest turnover with 4.7 million euros, in 2023. From antiparasitic products, ectoparasiticides, insecticides and repellents (QP53) had thehighest turnover, reaching to 2.2 million euros in 2023 (47% of the turnover of antiparasitic products). The turnover of endectocides (QP54) was 1.3 million euros (28%). The turnover of anthelmintics (QP52) has been the most stable over the years, 0.6 million euros (14%) in 2023. The turnover of anti-protozoal substances (QP51) has been the lowest in recent years, accounting for 11% of the turnover of antiparasitic products.
Figure 3. Turnover of antiparasitic products in 2019–2023
Antiinfectives for Systemic Use
Turnover of antiinfectives
The turnover of antiinfectives was 3.5 million euros, in 2023. The most sold antibacterials for systemic use by turnover were pleuromutilins (QJ01XQ), 3rd-generation cephalosporins (QJ01DD), tetracyclines (QJ01AA), combinations of penicillins (QJ01CR) and penicillins with extended spectrum (QJ01CA).
Figure 4. Turnover of most sold antimicrobials in 2019–2023
The amount of sold antiinfectives by active ingredient
The amount of active ingredients sold in 2023 increased by 3% compared the previous year, reaching to 6.6 tons. The use of antimicrobial classes important in human medicine as sales of 3rd- and 4th- generation cephalosporins has decreased throughout last years.
Figure 5. Antibiotics for veterinary use in 2019–2023
Of the overall sales of antimicrobials in 2023, penicillins, tetracyclines and pleuromutilins accounted for the largest amounts.
Figure 6. Antimicrobials by classes in 2023
More than fifty different active ingredients of antibiotics are used for veterinary purposes in Estonia. The most sold active ingredients were tiamulin, doxycycline and amoxicillin.
Table 1. The most sold active ingredients (antibiotics) in 2019–2023 (sold in kilograms)
Active ingredient |
2019 |
2020 |
2021 |
2022 |
2023 |
|
|
1 |
Tiamulin |
956 |
997 |
1 209 |
1 172 |
1 331 |
|
2 |
Doxycycline |
1 509 |
1 359 |
1 320 |
1 381 |
1 244 |
|
3 |
Amoxicillin |
1 064 |
1 050 |
828 |
857 |
952 |
|
4 |
Benzylpenicillin |
697 |
571 |
553 |
493 |
859 |
|
5 |
Monensin |
709 |
767 |
732 |
813 |
583 |
|
6 |
Oxytetracycline |
245 |
220 |
241 |
157 |
180 |
|
7 |
Sulfamethoxazole |
393 |
402 |
217 |
234 |
179 |
|
8 |
Tylosin |
25 |
60 |
52 |
99 |
110 |
|
9 |
Dihydrostreptomycin |
285 |
312 |
255 |
166 |
104 |
|
10 |
Tylvalosin |
179 |
112 |
47 |
71 |
98 |
IMMUNOLOGICALS
In 2019–2023, the turnover of immunologicals (vaccines) remained between 2.9–3.7 million euros. 39% of immunologicals sold in 2023 were immunologicals for suidae, reaching 1.4 million euros, following by immunologicals for bovidae (26%) and for canidae (17%).
Figure 7. Turnover of immunologicals in 2019–2023
HUMAN MEDICINES FOR VETERINARY USE
In the absence of authorised veterinary medicine, veterinarian can use authorised human medicine if necessary. In 2023, the most sold human medicines for veterinary use were drugs for nervous system, blood and blood forming organs and sensory organs.
Figure 8. Human medicines sales for veterinary use in 2023
Last updated: 22.03.2024